Top 50 Biotech Startup Investors in China in January 2026

Investor	Biotech China investments
Qiming Venture Partners	57
HSG	42
BioVenture	33
Lilly Asia Ventures	29
Med-Fine Capital	27
Matrix Partners China	25
Kaitai Capital	25
Frees Fund	24
IDG Capital	22
Sherpa Healthcare Partners	22
Northern Light Venture Capital	19
Legend Capital	19
CDH Investments	18
TF Capital	18
Hillhouse Investment	17
Highlight Capital	15
CD Capital	15
Puhua Capital	14
Cowin Capital	14
Gaorong Capital	13
Cowin Venture	12
K2VC	12
Linear Capital	12
SDIC Venture Capital	12
Green Pine Capital Partners	12
Prox Ventures	12
BioTrack Capital	11
ZhenFund	11
Delian Capital	11
Addor Capital	11
Shenzhen Capital Group	11
LYFE Capital	11
Legend Star	11
Pan-Lin Capital	10
Shunwei Capital	10
Shunxi Fund	10
ZSVC	10
Empower Investment	10
Oriental Fortune Capital	10
Baidu Ventures	10
Hillhouse Investment	9
Source Code Capital	9
Hillhouse Ventures	9
Huagai Capital	9
EFung Capital	9
Goldport Capital	9
Decheng Capital	9
Redhill Capital	9
Lapam Capital	9
Sinovation Ventures	9

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
China, United States, Hong Kong

Portfolio highlights

Keystone — Kesytone is a hardware wallet for bitcoin, Ethereum, USDT, BCH, and cryptocurrencies.
Ronghe Medical — Ronghe Medical is a medical device manufacturer specializing in the design, research and development, production, and sales of high-end medical device systems based on advanced energy ablation technology platforms, delivering innovative therapeutic solutions that enhance clinical precision, improve patient outcomes, and support a wide range ofmedical applications.
InfStones — Founded in 2018 with offices across three countries and two continents, InfStones is the world's leading blockchain infrastructure provider. Currently, InfStones provides services to large institutional clients around the globe, supporting thousands of nodes on more than 50 public blockchains through its universal platform.

We help founders build enduring companies.

Investment focus

Health Care, Biotechnology, Artificial Intelligence
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

Investment focus

Health Care, Medical, Biotechnology
Series A, Series B, Seed
China, United States, Hong Kong

Portfolio highlights

AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

Enchannel — Enchannel Medical is a global innovation platform that focuses on electrophysiology and provides atrial fibrillation treatment solution around "3D mapping + PFA ablation".
Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
LYNK Pharmaceuticals — LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
China, United States

Portfolio highlights

BV Laser — BV Laser is a manufacturer of medical beauty equipment.
Allink Biotherapeutics — Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.
Excalipoint Therapetics — Excalipoint Therapeutics is a Private limited company.

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Investment focus

Health Care, Biotechnology, Software
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

Levostar — Levostar Biotech_Innovative Solutions for Innovative Therapies Levostar Biotech is a technology-driven enterprise focused on innovative technologies for Advanced Therapy Medicinal Products.
RoboParty — RoboParty is a bipedal robot technology company that specializes in research, development, and engineering of humanoid robots.
Ucello Therapeutics — Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.

KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Angel, Series B
China, United States

Portfolio highlights

OncoC4 — OncoC4 develops first-in-class and best-in-class medicines for hard-to-treat cancers by leveraging CTLA-4, CD24, and siglecs
Primelink Bio — Primelink Bio is a Biotechnology firm that is working to to develop next generation of drug delivery systems.
Sheng Sheng Biology — Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services.

By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.

Investment focus

Artificial Intelligence, Medical, Biotechnology
Series A, Seed, Angel
China, United States, Singapore

Portfolio highlights

Baiyao Technology — Baiyao Technology is a biopharmaceuticals company offering drug and treatment plan development utilizing AI simulation of life processes.
Boin Biotechnology — Boin Biotechnology is a cutting-edge biopharmaceutical company. The company is dedicated to the development of gene therapy drugs, with a particular focus on advancing the next generation of gene therapy.
Dingou Biopharmaceuticals — Dingou Biotechnology is a developer of allergen diagnosis and treatment products, mainly engaged in allergen-specific diagnosis and treatment business

IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector. Today they work with private equity and venture capital fund managers, investment advisors, and business entities from around the world. Their limited partners include many internationally reputable investors, including sovereign wealth funds,pension funds, institutional investors, major charities, university endowments, family offices, and business luminaries.IDG Capital brings a powerful combination of global perspective and local experience to investment management. As long-term value investors, they are highly skilled at mobilizing global resources to address local needs, especially for Inbound and outbound opportunities in China and the rest of Asia. Their highly skilled team has an in-depth understanding of the Chinese market and enjoys close relationships with many influential business leaders.

Investment focus

Software, Internet, E-Commerce
Series A, Series B, Series C
China, United States, India

Portfolio highlights

Kaiwuji — Kaiwuji is an emerging company in the AI4Materials field.
Hongxin Biology — Hongxin Bio is an mRNA drug developer, focusing on nucleic acid drug delivery and RNA drug development.
Rongguang Optics — Rongguang Optics is a company specializing in optical instrument manufacturing, along with vacuum coating processing, industrial design services, and plastic product manufacturing.

Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
China, United States, Kenya

Portfolio highlights

AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
PAQ Therapeutics — PAQ Therapeutics is developing KRAS degraders for deadly cancers without good treatment options.
Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.

Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.

Investment focus

Health Care, Medical, Biotechnology
Series A, Series B, Seed
China, United States, South Korea

Portfolio highlights

iRegene — iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases.
Wala English — Wala English is a provider of comprehensive full-process AI contextual learning services, leveraging artificial intelligence to deliver personalized, immersive language learning experiences that adapt to each learner’s needs, context, and progress throughout their educational journey.
Hertz Life Science Technology — Hertz Life Science Technology uses virus-like particle VLPs technology to develop animal and human vaccines.The company has several underlying core patented technologies and has established a stable and efficient research and development platform based on the Jiyin Biomedical Transformation (Greater Bay Area) base, and actively promotes theresearch and development of vaccines.At present, the company has carried out extensive and in-depth cooperation with large enterprises such as Qingdao Yibang and Wen's Group, and its R&D strength has been highly recognized by peers and upstream and downstream enterprises.

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Investment focus

Health Care, Medical, Biotechnology
Series B, Series A, Series C
China, United States, South Korea

Portfolio highlights

Obita — Obita is a B2B financial network that offers stablecoin-driven transactions for enterprises, merchants, and fintechs.
X Square — X Square is a company focused on developing universal embodied large models for robots, aiming to create a universal brain-cerebellum system that offers comprehensive capabilities from perception to action.
Neolix — Neolix is a technologically innovative company that specializes in the production of physical and sports scenes. Neolithic Century Technology is an innovative design team. Committed to design research, industrial design, structural engineering, product customization, providing customers with creative value enhancement services. Service customersinclude Lenovo, Siemens, Midea, GE, State Grid, CSIC, Honeywell, Bank of China, Agricultural Bank, etc.

CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.

Investment focus

Manufacturing, Health Care, Biotechnology
Series A, Series B, Series C
China, United States, Canada

Portfolio highlights

TMiRob — TMiRob is a medical robot developer that works with hospitals and clinics to develop medical robots to improve the work efficiency of medical workers. The medical robots developed by TMiRob can be used in medical treatment assistance and nursing services in hospitals and clinics.
SenseTime — SenseTime is a leading AI software company focused on creating a better AI-empowered future through innovation. Upholding a vision of advancing the interconnection of physical and digital worlds with AI, driving sustainable productivity growth and seamless interactive experiences, SenseTime is committed to advancing AI research, developing scalableand affordable AI software platforms that benefit businesses, people, and society, as well as attract and nurture top talents to shape the future together.With their roots in the academic world, we invest in original and cutting-edge research that allows them to offer and continuously improve industry-leading, full-stack AI capabilities, covering key fields across perception intelligence, decision intelligence, AI-enabled content generation, and AI-enabled content enhancement, as well as key capabilities in AI chips, sensors and computing infrastructure. Their proprietary AI infrastructure, SenseCore, allows us to develop powerful and efficient AI software platforms that are scalable and adaptable for a wide range of applications. Their technologies are trusted by customers and partners in many industry verticals including Smart Business, Smart City, Smart Life, and Smart Auto.SenseTime has been actively involved in the development of national and international industry standards on data security, privacy protection, ethical and sustainable AI. As of June 30, 2021, SenseTime has participated in the formulation of over 80 national or international industry standards, working closely with multiple domestic and multilateral institutions on ethical and sustainable AI development. SenseTime was the only AI company in Asia to have its Code of Ethics for AI Sustainable Development selected by the United Nations as one of the key publication references in the United Nations Resource Guide on AI Strategies published in June 2021.They have offices in markets including Hong Kong, Mainland China, Macau, Taiwan, Japan, Malaysia, Singapore, South Korea, Saudi Arabia, and the United Arab Emirates, among others, as well as a presence in Thailand, Indonesia, and the Philippines.
Spear Bio — Successive Proximity Extension Amplification Reaction (SPEAR) technology from Spear Bio enables ultra-sensitive biomarker detection using ultra-small samples.

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
China, United States

Portfolio highlights

Vybio — Vybio focuses on the research and development of new drugs for oncology and hepatitis B. The core members of the team have 30 years of experience in tumor and hepatitis B drug research and development, and come from well-known pharmaceutical companies such as WuXi AppTec, Pfizer, BMS, etc., using a specific tumor microenvironment to independentlyinnovate prodrug design and screening, and developed a series of global drugs. Preclinical research on precisely targeted small molecule anticancer prodrug compounds protected by intellectual property rights is being carried out in an orderly manner.
Huanxin Medical — Huanxin Medical is an innovative medical device company that specializes in the research and development of interventional medical devices.
Minghui Pharmaceutical — Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs.

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Series C
China, United States, Singapore

Portfolio highlights

Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
Horizon Continental Technology — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics

Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.

Investment focus

Health Care, Medical, Biotechnology
Series A, Series B, Seed
China, United States, Portugal

Portfolio highlights

VelaVigo — VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.
Realm of Illumination — Realm of Illumination is an AI smarter hardware developer that focuses on the research and development of AI smart terminal equipment and sensors to fulfill the application needs of artificial intelligence and the Internet of Things.
E-nitiate Biopharmaceuticals — E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research and development, and strategic collaborations, to address unmet medical needs and to improve the quality of human life.

CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Seed
China, United States

Portfolio highlights

Healingovation — Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.
Greenon Biotech — Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on.
Qihe Biotech — Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.

Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.

Investment focus

Health Care, Medical, Manufacturing
Series A, Series B, Seed
China, United Kingdom, United States

Portfolio highlights

Anten — Anten is a high-tech enterprise dedicated to the research, development, and production of innovative dietary supplements and precision nutrition technologies, aiming to promote personalized health and wellness solutions through scientifically backed formulations and cutting-edge biotechnological advancements.
Kangweijian Bio — Kangweijian Bio is a health food manufacturer and distributor dedicated to delivering safe, high-quality products and services across global markets, specializing in food and cosmetic raw materials, health food ingredients, pharmaceutical excipients, and animal nutrition.
Rongrui Technology — Rongrui Technology is an industrial enzyme developer, involved in industrial enzyme research and development; technical services, technology development, technology consulting, technology exchange, technology transfer, and technology promotion.

Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.

Investment focus

Manufacturing, Health Care, Biotechnology
Series A, Series B, Seed
China, Hong Kong, United States

Portfolio highlights

Yiqi Future — Yiqi Future is a cutting-edge high-tech company dedicated to the research, development, and innovation of advanced AI-powered physical therapy robots. With a strong focus on integrating artificial intelligence, robotics, and biomedical engineering, the company aims to revolutionize the rehabilitation and healthcare industry by providingintelligent, efficient, and personalized therapeutic solutions.
Zhongzhi Xinying — Zhongzhi Xinying is a laser processing solution provider focused on developing and applying laser technology. Its products serve industries such as aerospace, rail transportation, shipbuilding, IT manufacturing, and medical.
Pengnao Technology — Pengnao Technology is an innovative brain-computer interface company with independent intellectual property rights, dedicated to advancing neural interaction technologies that bridge the gap between the human brain and intelligent systems.

Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.

Investment focus

Information Technology, Artificial Intelligence, E-Commerce
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

Nova Fusion — Nova Fusion is an innovative company that provides commercialization of small modular nuclear fusion reactors.
Cornerstone Robotics — Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Neolix — Neolix is a technologically innovative company that specializes in the production of physical and sports scenes. Neolithic Century Technology is an innovative design team. Committed to design research, industrial design, structural engineering, product customization, providing customers with creative value enhancement services. Service customersinclude Lenovo, Siemens, Midea, GE, State Grid, CSIC, Honeywell, Bank of China, Agricultural Bank, etc.

Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.

Investment focus

Health Care, Biotechnology, Medical
Series A, Angel, Series B
China, United States, Canada

Portfolio highlights

Fine Vision — Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's WuhanOptoelectronics National Research Center under the Huazhong Technology Technology transition.
Guanchen Biotechnology — Guanchen Biotechnology is a developer of innovative cosmetic ingredients.
Excalipoint Therapetics — Excalipoint Therapeutics is a Private limited company.

K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.

Investment focus

E-Commerce, Manufacturing, Biotechnology
Series A, Seed, Angel
China, United States, Japan

Portfolio highlights

YolTech Therapeutics — Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.
Hangmo Technology — Hangmo Technology is a developer of advanced flexible robotics technology, primarily focused on the design and engineering of highly integrated robotic systems. The company specializes in creating compact, adaptable, and intelligent robotic solutions that can be applied across various industries, including manufacturing, healthcare, and serviceautomation
Cornerstone Robotics — Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.

Investment focus

Software, Artificial Intelligence, Biotechnology
Seed, Angel, Series A
China, Germany, Hong Kong

Portfolio highlights

BTRY — BTRY is a spin-off of EMPA and ETH and is developing the industry's first energy-dense solid-state battery, using sophisticated semiconductor manufacturing technologies.
TARS — Zhihang Zhong is a prominent researcher in the field of artificial intelligence, particularly known for his work on integrating spatial perception and reasoning into AI systems.
NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.

ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.

Investment focus

Manufacturing, Biotechnology, Electronics
Series B, Series A, Funding Round
China, United States, Hong Kong

Portfolio highlights

Yanshengchao — Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
AI² Robotics — AI² Robotics is an embodied intelligent robot company that offers research and development of general intelligent embodied terminals.
Shengde Chuangying — Shengde Chuangying is a biotechnology company, focuses on synthetic biology.

Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.

Investment focus

Software, Artificial Intelligence, Manufacturing
Series A, Series B, Angel
China, United States, Canada

Portfolio highlights

Sunrise — Sunrise is a high-performance GPU developer specializing in GPU research and development.
Shanmu SHANMU — Shanmu SHANMU is a micro medical robot specialist who uses self-developed digital microfluidic chipsets and artificial intelligence algorithms. The robot can continuously check the metabolic components in urine, establishing a link between the user's health status and disease and intelligently establishing multiple disease management cycles.
YolTech Therapeutics — Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.

Investment focus

Medical, Biotechnology, Health Care
Seed, Funding Round, Series A
China, United States, United Kingdom

Portfolio highlights

Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
Tuanxiang Pharmaceutical — Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology.
Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.

BioTrack Capital is a China-based investment firm.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Seed
China, United States, Singapore

Portfolio highlights

Spurious — Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies.
Cavan Auto — Cavan Auto specializes in the production of electric vehicles and hydrogen fuel cell-powered new energy.
Minghui Pharmaceutical — Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs.

ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.

Investment focus

Artificial Intelligence, Software, E-Commerce
Series A, Seed, Series B
China, United States, Singapore

Portfolio highlights

ChatCut — ChatCut lets you edit videos using natural language. Remove repeated takes, restructure content, and cut down for social media with simple prompts. Perfect for interviews and documentaries.
Yunwang Innovation — Yunwang Innovation is formed by marathon runners, rehabilitation therapist, industrial designers creating solutions for recovery.
Cornerstone Robotics — Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.

Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.

Investment focus

Biotechnology, Manufacturing, Health Care
Series A, Seed, Series B
China, United States, France

Portfolio highlights

Kangweijian Bio — Kangweijian Bio is a health food manufacturer and distributor dedicated to delivering safe, high-quality products and services across global markets, specializing in food and cosmetic raw materials, health food ingredients, pharmaceutical excipients, and animal nutrition.
Core Medical Technology — Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.
Lingji Tianci Technology — Lingji Tianci is an innovative technology company specializing in AI companionship solutions for children, focusing on “AI family interactive social” products and smart hardware. The company aims to become the “Nintendo” of the children’s AI development partner sector, leveraging intelligent hardware and proprietary AI content to create interactiveexperiences that encourage exploration and growth for families and children.

Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.

Investment focus

Manufacturing, Semiconductor, Electronics
Series A, Series B, Funding Round
China, Hong Kong, United States

Portfolio highlights

Raysun Technology — Raysun Technology is a enterprise specializing in the development, and manufacturing of laser equipment for the semiconductor industry.
Baining Yingchuang — Baining Yingchuang focuses on the R&D and industrialization of high-end medical devices related to the perioperative period,
Heguang New Energy — Heguang New Energy is China's largest producer of square silicon cores for polysilicon and has long-term and stable purchase agreements with a number of major polysilicon producers.

Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.

Investment focus

Manufacturing, Health Care, Information Technology
Series A, Series B, Series C
China, United States, Japan

Portfolio highlights

Biosun Pharma — Biosun Pharma is an innovative biopharmaceutical company that specializes in the production of drugs for tumors, self-immune diseases, and inflammatory diseases.
Tuowei Tianhai — TWTH committed to minimizing export costs of logistics in China by establishing the most convenient and efficient Sino-US transport brand. It is dedicated to providing Sino-US ocean freight LCL Door-to-Door service, air freight Door-to-Door service, ocean freight FCL Door-to-Door service, international express service, CNRAM and otherinternational freight services.
Yuchuang Semiconductor — Erised Semiconductor is a circuit designer and manufacturer that provides users with display driver and power management chips. The applications can be found in radiofrequency applications, discrete devices, and other products.

LYFE Capital is a pure play healthcare focused investment firm. We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters inSingapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe. LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
China, United States, France

Portfolio highlights

CytoTronics — CytoTronics is designing and developing cell culture plates with embedded high-density electronic systems.
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Angel
China, United States, France

Portfolio highlights

VelaVigo — VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals.
Zhizai Wujie — Zhizai Wujie is a robotics company that specializes in research, development, and application of humanoid robots.
Direct Drive Technology — Direct Drive Technology provides direct drive solutions to replace the reduction gears in any machine. The company has a complete set of technologies for robot joints from sensors, drivers to motor bodies. Drive Tech uses a unique direct drive precise & powerful motion solution, thereby helping many other industries to boost different products.

Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。

Investment focus

Health Care, Biotechnology, Medical
Series A, Seed, Series B
China, United States, Canada

Portfolio highlights

Libo Biotech — Libo Biotech is a cutting-edge biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics that specifically target RNA.
Huarui Shuxin — Huarui Shuxin develops high-performance and high-reliability domestic RAID control cards in the field of core storage hardware.
Suzhou Ribo Life Science — Established in 2007, Suzhou Ribo Life Science Co. Ltd. is devoted to the advanced oligonucleotide therapeutics in China including siRNA, antisense and aptamer drugs based on proprietary intellectual properties.

Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.

Investment focus

Manufacturing, Software, Internet
Series A, Series B, Series C
China, India, United States

Portfolio highlights

Darma — DARMA - Digital Healt
Realm of Illumination — Realm of Illumination is an AI smarter hardware developer that focuses on the research and development of AI smart terminal equipment and sensors to fulfill the application needs of artificial intelligence and the Internet of Things.
Shouxing Technology — AheadForm is pioneering the development of realistic humanoid robots designed to revolutionize human-robot interaction. Our current focus is on creating sophisticated humanoid robot heads that can express emotions, perceive their environment, and interact seamlessly with humans. By combining cutting-edge AI and advanced robotics, we aim to bring life to machines and transform the way humans engage with technology.

Shunxi Fund is an investment Fund. It is managed by Beijing State-owned Capital Operations and Management.

Investment focus

Manufacturing, Biotechnology, Health Care
Series A, Seed, Series B
China

Portfolio highlights

Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
Lingchuan Technology — Lingchuan Technology is a leading provider of software development services, offering innovative and customized solutions to meet the diverse needs of clients across various industries.

ZSVC is a Chinese venture capital firm specialized in seed and early stage investments.

Investment focus

Manufacturing, Medical, Health Care
Series A, Seed, Series B
China, United States, India

Portfolio highlights

Micot — Micot is a new molecular entity drug developer for peptides, dedicated to the development of innovative drugs, multi- and protein-based innovative biopharmaceuticals, vaccines and biomolecular drug delivery systems and products, and for drug screening and biopharmaceutical research. The technology combines to provide users with Bio-Res-Deliv, abiological macromolecular respiratory drug delivery system, suitable for the treatment of cardiovascular diseases, metabolic diseases, liver diseases and the like.
Deruicore — Deruicore is an integrated research and development based manufacturing company.
Zhisheng Bio — Zhisheng Bio specialzies in product research and development, and market transformation of biopharmaceutical products.

Empower Investment was founded in 2012 in Shanghai, China. Their investment covers early-stage ventures, mid-stage growth, and securities in the public market. With headquarters in Shanghai, the company established branch offices in Beijing, Shenzhen, Hangzhou and Chengdu. Empower Investment has invested in over 150 high-tech and high-growthcompanies on a global scale covering regions including China, U.S, India, South Korea, Vietnam and Hong Kong. Their portfolio companies include fast-growing industries such as internet, AI, big data, automation & robotics, financial technology, cultural creativity, advanced materials, and healthcare.The Empower team has extensive experience in both deep technologies and financial services including internet, computer science, electronic engineering, materials science, auditing and investment banking. Some team members were serial entrepreneurs. With candidness and empathy, the team is eager to find and partner with the most visionary, determined and down-to-earth entrepreneurs. It always brings great excitement and pleasure to build a bright future with them.

Investment focus

Information Technology, Artificial Intelligence, Health Care
Angel, Series A, Seed
China, United States, India

Portfolio highlights

SideChef — Your digital resource for all home cooking needs. Browse 18,000 step-by-step recipes personalized to your diet and taste, for every skill level.
Hongpeng Airlines — Hongpeng Airlines is committed to developing, designing, and producing low-cost airplane engines.
Xunyuan Technology — Xunyuan Technology is a bio-refining and bio-manufacturing platform company based on non-grain carbon sources.

Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.

Investment focus

Manufacturing, Software, Information Technology
Series A, Series B, Seed
China, United States

Portfolio highlights

Soundbridge AI — Soundbridge AI specializes in developing cutting-edge, AI-powered speech rehabilitation solutions designed to assist individuals with speech impairments in improving communication skills through personalized, adaptive therapy.
Xuanchuang Robotics — Xuanchuang Robotics is a leading provider of cutting-edge intelligent operations and maintenance solutions, specializing in advanced robotics technologies.
West Lake Intelligent Vision — West Lake Intelligent Vision is a developer of artificial intelligence and computational imaging fusion technology.

Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains

Investment focus

Artificial Intelligence, Health Care, Biotechnology
Series A, Seed, Series B
China, United States, Singapore

Portfolio highlights

InsForge — InsForge is the backend built for AI-assisted development. Connect InsForge with any agent. Add authentication, database, storage, functions, and AI integrations to your app in seconds.
Fastlane — We take innovative brands global. Fastlane is a full-service D2C solutions provider that assists enterprises with brand development, business infrastructure, and sales creation/growth in European, North American and Asian markets. We offer a superior one-stop solution, with expertise in go-to-market strategy, traditional and digital marketing,PR, logistics, e-commerce, sales, and platform development. We work with companies big and small, and our custom-tailored solutions range in scope from basic consulting services to 360° turnkey operations.
Zhongke Jiahe — Zhongke Jiahe develops compilation technology and aspires to build a universal, low-cost, high-performance fundamental software tool chain.

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Investment focus

Manufacturing, Biotechnology, Software
Series A, Series B, Series C
China, United States, Singapore

Portfolio highlights

CarDekho — Thinking of buying a car? At CarDekho.com, buy new and used cars, search by filter and preferences, compare cars, read latest news and updates, see 360 views & more!
Pulse — Pulse is a health care service provider that assess coronary physiology and biomechanics through innovative techniques.
Paper Boat — Paper Boat healthy and tasty nuts and trail mixes delivered at your doorstep. Our ingredients are prepared individually - our nuts are slow-roasted to preserve its original flavour & maintain crunchiness, our berries are tossed in beautiful aromatic spices, and then combined to bring the perfect balance of flavours.

Founded in 2014, Source Code Capital is a leading China VC focused on the broad TMT sectors and investing in both early stage start-ups and growth stage companies. With $1.5 billion and RMB 3.5 billion under management, Source Code Capital has been successfully partnering with close to 150 leading Chinese technology founders since inceptionincluding Bytedance, Meituan, Homelink, among many others. Source Code is focused on the “Big 3” fundamental drivers, which are Internet+, AI+, and Global+ , and invests along sectors such as media and entertainment, consumer services, enterprise, finance, retail, transportation, housing, education, and healthcare.

Investment focus

Software, Artificial Intelligence, E-Commerce
Series A, Series B, Series C
China, United States, Singapore

Portfolio highlights

Mootion — Mootion is an AI video generation platform. It enables detailed 3D motion control, character replacements, and background adjustments. This aims to streamline the production process for users.
Accelerating Evolution — Accelerating Evolution is a humanoid robotics company. It provides humanoid robots to AI firms and research institutes, as well as quick mass production and supply of standard items.
Guduwai Chinese Hamburger — Guduwai Chinese Hamburger is a brand of Hunan Guduwai Catering Management. It combines traditional pastry craftsmanship with modern hamburger forms.

Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.

Investment focus

Manufacturing, Biotechnology, Health Care
Series A, Series B, Seed
China, Singapore, Norway

Portfolio highlights

RoboticPlus.AI — RoboticPlus.AI is an robtics company that helps in architectural tech by providing intelligent robotic products for the construction sector.
HEMO BIOENGINEERING — HEMO BIOENGINEERING develops and provides innovative interventional medical devices to patients.
Hecheng New Materials Technology — Hecheng New Materials Technology is a manufacturing company offering bearing electrical corrosion and electrical insulation solutions.

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Seed
China, United States, Germany

Portfolio highlights

ViGeneron — ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vectorplatform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
Moyang Biotechnology — Moyang Biotechnology specializes in the development and consulting services of medical biomaterials for beauty sector.
Index Technology — Index Technology is a company that specializes in applying artificial intelligence technology to electronic design and production. Index Technology uses generative AI technology to optimize the traditional R&D process for electrical devices, and it offers automated generation services ranging from product requirements to PCBA manufacturingdesigns and supporting embedded programs.

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series C, Series B
China, United States, India

Portfolio highlights

QureBio — QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug developmentincluding phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform.The company was founded in 2017 and is based in Pudong District, Shanghai.
Pleryon Therapeutics — Innovations in biofunctional polymers
Tingsheng Technology — TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model.

Goldport Capital is a Shenzhen-based asset management company.

Investment focus

Manufacturing, Medical, Semiconductor
Series A, Seed, Angel
China

Portfolio highlights

Yurucheng — Yurucheng is a brand of oral materials, specializing in the R&D, production, sales and service of medical oral materials and oral equipment.
Zinc Core Titanium — Zinc Core Titanium makes special materials that light up and tiny screens for displays.
Rongxin New Materials — Rongxin New Materials is a developer specializing in graphene material science and technology, with a commitment to the research and development of new materials technology and engineering applications. The company focuses on graphene-based heating films and graphene-integrated thermal products that are designed to provide efficient and uniformheating solutions for both consumer and industrial sectors.

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Canada

Portfolio highlights

Excellergy — Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases.
Ottimo Pharma — Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden.
YolTech Therapeutics — Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

Redhill Capital is a venture capital firm specializing in early stage investment. It primary invests in medical industry.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A, Funding Round
China

Portfolio highlights

Douli — Douli is an employee service platform that provides welfare solutions for enterprises. They offer services in the fields of clothing, food, housing, transportation, medical care, entertainment, and more by combining online and offline multi-channel resources.
Inflamax Pharmaceuticals — Inflamax Pharmaceuticals is a biomedical technology company that specializes in the innovation and development of immune-inflammatory drugs.
EnCureGen Pharmaceuticals — Huizhengqi Medicine is a pharmaceutical company that develops mRNA drugs for the treatment of tumor and immunity diseases.

Lapam Capital is a healthcare-focused venture capital firm.

Investment focus

Biotechnology, Pharmaceutical, Medical
Series A, Series B, Series C
China, United States

Portfolio highlights

Enchannel — Enchannel Medical is a global innovation platform that focuses on electrophysiology and provides atrial fibrillation treatment solution around "3D mapping + PFA ablation".
LTZ Therapeutics — LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Lingtai Biotechnology — Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.

Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.

Investment focus

Software, Artificial Intelligence, Internet
Series A, Seed, Series B
China, United States, Singapore

Portfolio highlights

HPC-AI Technology — HPC-AI Technology provides a cloud-based platform to enhance AI computations by increasing CPU and GPU processing speeds.
Lanzhou Technology — Lanzhou Technology is a cognitive intelligence company that provides business insights products.
SiliconFlow — Silicon Mobile Technology is an AI infrastructure company that specilaizes in large models inference and deployment system to reduce the cost in the AIGC and LLM industries.